The BRD4 Inhibitor dBET57 Exerts Anticancer Effects by Targeting Superenhancer-Related Genes in Neuroblastoma

New frontiers in the discovery and development of PROTACs

(2022) Samir H. Barghout   Anti-Cancer Agents in Medicinal Chemistry

BRD4 inhibitor MZ1 exerts anti-cancer effects by targeting MYCN and MAPK signaling in neuroblastoma

(2022) Xianbing Zhang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Targeted BRD4 protein degradation by dBET1 ameliorates acute ischemic brain injury and improves functional outcomes associated with reduced neuroinflammation and oxidative stress and preservation of blood–brain barrier integrity

(2022) Lei Liu et al.   Journal of Neuroinflammation

Super-enhancer-associated INSM2 regulates lipid metabolism by modulating mTOR signaling pathway in neuroblastoma

(2022) Haibo Cao et al.   Cell and Bioscience

Super-enhancer-associated TTC8 alters the nucleocytoplasmic distribution of PHOX2B and activates MAPK signaling in neuroblastoma

(2022) Ran Zhuo et al.   Genes and Diseases

The quest to develop an effective therapy for neuroblastoma

(2021) Praveen Bhoopathi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Combining inhibitors of Brd4 and cyclin-dependent kinase can decrease tumor growth in neuroblastoma with MYCN amplification

(2021) Lauren Wood et al.   JOURNAL OF PEDIATRIC SURGERY

Targeting CDK9 for Anti-Cancer Therapeutics

(2021) Ranadip Mandal et al.   Cancers

Control Analysis of Protein-Protein Interaction Network Reveals Potential Regulatory Targets for MYCN

(2021) Chunyu Pan et al.   Frontiers in Oncology

The MicroRNA Landscape of MYCN-Amplified Neuroblastoma

(2021) Danny Misiak et al.   Frontiers in Oncology

ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency

(2021) Zhendong Cao et al.   MOLECULAR CELL

Methodological advances in the discovery of novel neuroblastoma therapeutics

(2021) Miguel F. Segura et al.   Expert Opinion on Drug Discovery

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics

(2020) Sajid Khan et al.   ONCOGENE

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

(2020) Evon Poon et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeted protein degradation: elements of PROTAC design

(2019) Stacey-Lynn Paiva et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Neuroblastoma

(2018) Akira Nakagawara et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Plasticity in binding confers selectivity in ligand-induced protein degradation

(2018) Radosław P. Nowak et al.   Nature Chemical Biology

Hitting two oncogenic machineries in cancer cells: cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells

(2018) Karin Bauer et al.   Oncotarget

Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma

(2018) Joshua Felgenhauer et al.   NEOPLASIA

BRD4 and Cancer: going beyond transcriptional regulation

(2018) Benedetta Donati et al.   Molecular Cancer

TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets

(2018) Bieke Decaesteker et al.   Nature Communications

BET Proteins as Targets for Anticancer Treatment

(2017) Anastasios Stathis et al.   Cancer Discovery

The MYCN Protein in Health and Disease

(2017) María Victoria Ruiz-Pérez et al.   Genes

Neuroblastoma

(2016) Katherine K. Matthay et al.   Nature Reviews Disease Primers

A LIN28B-RAN-AURKA Signaling Network Promotes Neuroblastoma Tumorigenesis

(2015) Robert W. Schnepp et al.   CANCER CELL

Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition

(2015) A. Henssen et al.   CLINICAL CANCER RESEARCH

Bromodomain inhibition by JQ1 suppresses lipopolysaccharide-stimulated interleukin-6 secretion in multiple myeloma cells

(2015) Rohit R. Ghurye et al.   CYTOKINE

TERT rearrangements are frequent in neuroblastoma and identify aggressive tumors

(2015) Linda J Valentijn et al.   NATURE GENETICS

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

(2013) Jakob Lovén et al.   CELL

BET Bromodomain Inhibition of MYC-Amplified Medulloblastoma

(2013) P. Bandopadhayay et al.   CLINICAL CANCER RESEARCH

MG132, a proteasome inhibitor, induces apoptosis in tumor cells

(2012) Na GUO et al.   Asia-Pacific Journal of Clinical Oncology

Recent Advances in Neuroblastoma

(2010) John M. Maris   NEW ENGLAND JOURNAL OF MEDICINE

PHOX2BIs a Novel and Specific Marker for Minimal Residual Disease Testing in Neuroblastoma

(2008) Janine Stutterheim et al.   JOURNAL OF CLINICAL ONCOLOGY